The role of resveratrol in the management of metabolic dysregulations in non-alcoholic fatty liver disease: a randomised placebo controlled clinical trial

Phase 2

Active, not recruiting

• Conditions: non-alcoholic fatty liver disease; Metabolic and Endocrine - Metabolic disorders; Diet and Nutrition - Obesity; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12612001135808
• Lead Sponsor: Metro-South Queensland health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

Diagnosed with NAFLD on ultrasound

Exclusion Criteria

-Viral hepatitis or other known cause for non-alcoholic liver disease such as use of hepato-toxic medications (eg. tamoxifen, methatrexane)
-Presence of metallic implants unsuitable for magnetic resonance, or a pace-maker
-Cirrhosis
-Ethanol consumption above 40g daily
-Type 1 or 2 diabetes
-Allergy to polyphenols
-Inability undergo all investigations

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Degree of peripheral insulin resistance measured by the euglycemic hyperinsulinemic clamp method[Baseline and at the end of study (8 weeks)]